|
Name |
asperthrin F
|
| Molecular Formula | C26H31N3O6 | |
| IUPAC Name* |
10-hydroxy-25-(hydroxymethyl)-19,19,26,26-tetramethyl-18,24-dioxa-7,12,23-triazaheptacyclo[11.10.3.01,13.02,11.04,9.014,22.015,20]hexacosa-2(11),3,15(20),16,21-pentaene-3,8-dione
|
|
| SMILES |
CC1(C)C=Cc2c(ccc3c2NC24N5C(=O)C6(O)CCCN6C(=O)C5CC32OC(CO)C4(C)C)O1
|
|
| InChI |
InChI=1S/C26H31N3O6/c1-22(2)10-8-14-17(34-22)7-6-15-19(14)27-26-23(3,4)18(13-30)35-24(15,26)12-16-20(31)28-11-5-9-25(28,33)21(32)29(16)26/h6-8,10,16,18,27,30,33H,5,9,11-13H2,1-4H3/t16-,18+,24+,25-,26-/m0/s1
|
|
| InChIKey |
NWGFWOCPCGSAFK-LKFMNQBISA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 481.55 | ALogp: | 1.5 |
| HBD: | 3 | HBA: | 7 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 111.6 | Aromatic Rings: | 7 |
| Heavy Atoms: | 35 | QED Weighted: | 0.563 |
| Caco-2 Permeability: | -5.001 | MDCK Permeability: | 0.00002770 |
| Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.282 | 20% Bioavailability (F20%): | 0.961 |
| 30% Bioavailability (F30%): | 0.932 |
| Blood-Brain-Barrier Penetration (BBB): | 0.09 | Plasma Protein Binding (PPB): | 75.68% |
| Volume Distribution (VD): | 1.341 | Fu: | 24.65% |
| CYP1A2-inhibitor: | 0.006 | CYP1A2-substrate: | 0.104 |
| CYP2C19-inhibitor: | 0.487 | CYP2C19-substrate: | 0.9 |
| CYP2C9-inhibitor: | 0.877 | CYP2C9-substrate: | 0.117 |
| CYP2D6-inhibitor: | 0.059 | CYP2D6-substrate: | 0.1 |
| CYP3A4-inhibitor: | 0.962 | CYP3A4-substrate: | 0.971 |
| Clearance (CL): | 8.575 | Half-life (T1/2): | 0.096 |
| hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.231 |
| Drug-inuced Liver Injury (DILI): | 0.864 | AMES Toxicity: | 0.023 |
| Rat Oral Acute Toxicity: | 0.936 | Maximum Recommended Daily Dose: | 0.917 |
| Skin Sensitization: | 0.213 | Carcinogencity: | 0.943 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.509 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004065 | ![]() |
1.000 | D02JNM | ![]() |
0.252 | ||
| ENC004064 | ![]() |
0.745 | D02QJH | ![]() |
0.245 | ||
| ENC002052 | ![]() |
0.516 | D06YFA | ![]() |
0.234 | ||
| ENC002538 | ![]() |
0.508 | D02IQY | ![]() |
0.227 | ||
| ENC002534 | ![]() |
0.500 | D0IL7L | ![]() |
0.226 | ||
| ENC002536 | ![]() |
0.500 | D0P0HT | ![]() |
0.225 | ||
| ENC002366 | ![]() |
0.500 | D08PIQ | ![]() |
0.223 | ||
| ENC004071 | ![]() |
0.492 | D0I5DS | ![]() |
0.223 | ||
| ENC002365 | ![]() |
0.492 | D0W7RJ | ![]() |
0.223 | ||
| ENC005468 | ![]() |
0.488 | D0Y2YP | ![]() |
0.223 | ||